TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with ...
Tectonic Therapeutic, Inc.'s stock surged 120% on positive Phase 1b data for TX45 in treating PH-HFpEF, offering a potential ...
Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...
Tectonic Therapeutic (TECX) stock surges on positive interim data from Phase 1b trial for lead candidate TX45 in patients ...
Tectonic Therapeutic TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction ...
TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...
Tectonic Therapeutic is a biotechnology company focused on the development of novel therapies for cardiovascular diseases, particularly those involving pulmonary hypertension and heart failure. Its ...
Shares of Tectonic plummeted 41% Tuesday following news that a similar drug developed by Eli Lilly (NYSE: LLY) for chronic ...
The trial's safety results were reassuring, with no serious adverse events or significant changes in vital signs, physical exams, or safety laboratory values post-administration of TX45. Transient ...